CROSS-LINKING OLIGONUCLEOTIDES FOR CHEMOTHERAPY

Award Information
Agency:
Department of Health and Human Services
Branch
n/a
Amount:
$412,000.00
Award Year:
1989
Program:
SBIR
Phase:
Phase II
Contract:
n/a
Agency Tracking Number:
7153
Solicitation Year:
n/a
Solicitation Topic Code:
n/a
Solicitation Number:
n/a
Small Business Information
Microprobe Corp.
1725 220th St Southeast #104, Bothell, WA, 98021
Hubzone Owned:
N
Socially and Economically Disadvantaged:
N
Woman Owned:
N
Duns:
n/a
Principal Investigator:
Rich B Meyer Jr Phd
(206) 485-8566
Business Contact:
() -
Research Institution:
n/a
Abstract
SHORT OLIGODEOXYNUCLEOTIDES INCORPORATING NUCLEOTIDES MODIFIED BY THE ADDITION OF REACTIVE CROSS-LINKING ARMS WILLBE SYNTHESIZED. THESE OLIGONUCLEOTIDES SHOULD HYBRIDIZE WITH TARGET SEQUENCES IN MRNA OR DNA AND, ONCE BOUND, SHOULDCOVALENTLY CROSS-LINK WITH THE COMPLEMENTARY SEQUENCE VIA THE INCORPORATED MODIFIED NUCLEOTIDE. IN PARTICULAR, DERIVATIVES OF 4-AMINOPYRAZOLO(3,4-D)PYRIMIDINE, WITH A HALOALKYL OR SIMILAR SUBSTITUENT IN THE 3-POSITION, WILL BE PREPARED. THESE DERIVATIVES ARE ISOSTERIC WITH A 7-SUBSTITUTED PURINE AND SHOULD BE CAPABLE OF CROSS-LINKING WITH THE 7-POSITION OF A PURINE IN AN ADJACENT BASE PAIR OF THE COMPLEMENTARY STRAND. THIS MODIFIED NUCLEOSIDE WILL BE CONVERTED INTO A BLOCKED PHOSPHORAMIDITE AND INCORPORATED INTO AN OLIGONUCLEOTIDE ON A DNA SYNTHESIZER. THIS OLIGONUCLEOTIDE WILL BE TESTED FOR COVALENT CROSS-LINKING TO COMPLEMENTARY AND NONCOMPLEMENTARYDNA RESTRICTION FRAGMENTS. SUCH ANTISENSE, CROSS-LINKABLE OLIGONUCLEOTIDES, DESIGNED TO MINIMIZE HOST TOXICITY, MAY BE USEFUL AS CHEMOTHERAPEUTIC AGENTS FOR INFECTIOUS DISEASESAND CANCER. THEY WILL BE TARGETED AT THE MRNA OR DNA OF MICROORGANISMS OR OF ANY CANCER TISSUE IN WHICH ARREARRANGEDONCOGENE IS EXPRESSED.

* information listed above is at the time of submission.

Agency Micro-sites

US Flag An Official Website of the United States Government